Nuvectis Pharma, Inc. (NVCT)
18.94
+0.34
(+1.83%)
USD |
NASDAQ |
Oct 19, 16:00
18.94
0.00 (0.00%)
After-Hours: 16:21
Nuvectis Pharma Enterprise Value : 474.36M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 474.36M |
| October 15, 2026 | 483.17M |
| October 14, 2026 | 458.35M |
| October 13, 2026 | 462.35M |
| October 12, 2026 | 503.46M |
| October 09, 2026 | 541.63M |
| October 08, 2026 | 515.21M |
| October 07, 2026 | 519.48M |
| October 06, 2026 | 512.54M |
| October 05, 2026 | 548.84M |
| October 02, 2026 | 562.99M |
| October 01, 2026 | 530.96M |
| September 30, 2026 | 541.63M |
| September 29, 2026 | 525.88M |
| September 28, 2026 | 533.36M |
| September 25, 2026 | 517.61M |
| September 24, 2026 | 555.25M |
| September 23, 2026 | 540.30M |
| September 22, 2026 | 591.82M |
| September 21, 2026 | 564.59M |
| September 18, 2026 | 565.13M |
| September 17, 2026 | 548.57M |
| September 16, 2026 | 561.66M |
| September 15, 2026 | 562.99M |
| September 14, 2026 | 601.16M |
| Date | Value |
|---|---|
| September 11, 2026 | 618.25M |
| September 10, 2026 | 578.21M |
| September 09, 2026 | 585.95M |
| September 08, 2026 | 618.25M |
| September 04, 2026 | 631.60M |
| September 03, 2026 | 628.39M |
| September 02, 2026 | 616.38M |
| September 01, 2026 | 593.42M |
| August 31, 2026 | 584.61M |
| August 28, 2026 | 611.31M |
| August 27, 2026 | 650.28M |
| August 26, 2026 | 645.21M |
| August 25, 2026 | 668.97M |
| August 24, 2026 | 615.04M |
| August 21, 2026 | 606.77M |
| August 20, 2026 | 601.16M |
| August 19, 2026 | 600.63M |
| August 18, 2026 | 536.03M |
| August 17, 2026 | 487.18M |
| August 14, 2026 | 483.97M |
| August 13, 2026 | 491.18M |
| August 12, 2026 | 499.46M |
| August 11, 2026 | 495.99M |
| August 10, 2026 | 481.70M |
| August 07, 2026 | 483.71M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Opus Genetics, Inc. | 264.76M |
| Faeth Therapeutics, Inc. | 306.58M |
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.02M |
| Total Expenses (Quarterly) | 7.02M |
| EPS Diluted (Quarterly) | -0.299 |
| Earnings Yield | -6.75% |
| Normalized Earnings Yield | -6.745 |